|Bid||135.2000 x 800|
|Ask||135.2200 x 600|
|Day's Range||134.3500 - 135.7900|
|52 Week Range||109.3200 - 137.0800|
|PE Ratio (TTM)||22.90|
|Dividend & Yield||3.36 (2.50%)|
|1y Target Est||N/A|
A month after he said he would, President Trump has yet to declare the opioid epidemic a national...
Alkermes (ALKS) announced encouraging results from a phase IV study of ARISTADA for the treatment of schizophrenia.
U.S. companies that have significant sales in Europe are about to reap the benefits of a weak greenback. These big-names will especially be winners.